More importantly, FASN expression was significantly negatively correlated with PD-1 in multiple cancers, and its expression has significant prognostic significance for anti-PD-1 and anti-PD-L1 immunotherapy, which has also been validated in immunotherapy prognostic outcomes for GBM. Here, CD274 is linked to glioblastoma.